Related Experiment Videos
Immunomodulation therapy in colorectal carcinoma.
D Yip1, A H Strickland, C S Karapetis
1Department of Medical Oncology, Guy's Hospital, St Thomas St, London, UK.
Cancer Treatment Reviews
|May 18, 2000
Summary
Immunotherapy shows promise for colorectal cancer treatment. Specific therapies, like monoclonal antibodies and vaccines, are demonstrating reduced relapse and mortality rates, offering a low-toxicity option alongside chemotherapy.
Area of Science:
- Oncology
- Immunology
Background:
- Significant advancements in understanding the immune system's role in colorectal cancer (CRC).
- Immunomodulatory therapy is being explored for adjuvant and palliative CRC treatment.
Purpose of the Study:
- To review the progress and efficacy of immunotherapies in colorectal cancer treatment.
- To evaluate the potential of specific immunotherapies compared to non-specific approaches.
Main Methods:
- Review of clinical trials and studies on various immunomodulatory agents for CRC.
- Analysis of outcomes for non-specific immunotherapies (levamisole, cimetidine, interferon, BCG).
- Evaluation of results from specific immunotherapies including monoclonal antibodies (edrecolomab, 3H1, 105AD7) and autologous tumor vaccines.
Main Results:
- Non-specific immunotherapies showed limited clinical benefits in randomized trials.
- Edrecolomab demonstrated reduced relapse and mortality in Dukes' C CRC post-surgery.
- Autologous tumor vaccines showed benefits in Dukes' B CRC.
- Antibodies 3H1 and 105AD7 showed in-vitro and in-vivo immune activation against CRC.
Conclusions:
- Specific immunotherapies, including monoclonal antibodies and vaccines, show promising results in CRC treatment.
- These agents are under investigation in randomized trials for survival benefits.
- Immunotherapy offers a potential low-toxicity adjunct to conventional CRC chemotherapy.